Chardan Capital Issues a Hold Rating on Voyager Therapeutics Inc

By Ryan Adsit

Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Voyager Therapeutics Inc (NASDAQ: VYGR) today and set a price target of $13. The company’s shares closed yesterday at $11.21.

According to TipRanks.com, Amusa is ranked 0 out of 5 stars with an average return of -5.6% and a 43.5% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Dimension Therapeutics Inc, and Lion Biotechnologies Inc.

Voyager Therapeutics Inc has an analyst consensus of Moderate Buy.

The company has a one year high of $18.25 and a one year low of $8.30. Currently, Voyager Therapeutics Inc has an average volume of 79.92K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops gene therapies for fatal and debilitating diseases of the central nervous system. It focuses in the field of adeno-associated virus gene therapy through innovation and investment in vector optimization and engineering, and dosing techniques, as well as process development and production. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.